Sino Biological US Inc

« Previous article
Sino Biological Inve...

24th March 2022  Content supplied by: Sino Biological US Inc.

Recombinant Antigens for 2022-2023 Influenza Vaccine Strains

Vaccination is the most effective way to prevent flu infection. Each year, several different flu strains are selected as vaccine candidates based on surveillance data of the recent isolates and the performance of the vaccines from the previous season. In recent decades, most influenza vaccines are trivalent or quadrivalent, composed of one H1N1, one H3N2, and either one or two type B viruses (Yamagata and Victoria lineage).

Sino Biological offers recombinant flu antigen products under its ProVir™ viral antigen collection. The product line covers Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP) proteins from all WHO-recommended vaccine strains in recent years. These antigens can be used to analyze vaccine-induced antibody response.

In addition, Sino Biological also develops a large collection of monoclonal antibodies against the flu antigens. These reagents can help facilitate relevant assay development.

Visit Sino Biological or click on the Request Information button below.

Share on:


Date Published: 24th March 2022

Source article link: View

View full company details

Sino Biological US Inc.


Wayne, PA 19087

United States

Tel: +1 215-583-7898

Email Supplier

View full company details

Related news from Sino Biological US Inc.